MARKET WIREReuters • 1h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
Why RNTX Stock dropped -7.79% Today — RQD Quant Desk Flash
$0.67 -7.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.66
Rein Therapeutics Inc. (RNTX) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $62.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RNTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RNTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Rein Therapeutics Inc. (NASDAQ: RNTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.67 (-7.79% 1D, market cap $62.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RNTX ranks #315 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RNTX compare to INCR and SPRO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNTX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INCR (Intercure Ltd.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $61.8M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RNTX?
▼
Per RNTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001420565), Rein Therapeutics Inc. generated $0 in revenue, -$49.9M in net income, and -$19.4M in free cash flow against $24.2M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.66 (-1.59%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY RNTX SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (31% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (27% of score)
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 47.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$0.79-25.3% Next Q
57
Q2 (-2Q)Grade C-$0.59-1.7% Next Q
54
Q3 (-1Q)Grade C-$0.58+15.5% Next Q
52
CurrentGrade D$0.67-5.4% Hist 90D α
49
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RNTX Turnaround Squeeze
While RNTX currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.75) and Max Pain ($0.70) forces dealer call-delta covering toward $2.29.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RNTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RNTX Stock dropped -7.79% Today — RQD Quant Desk Flash
Rein Therapeutics Inc. (RNTX) dropped -7.79% to $0.67, trading at 8% of its 52-week range ($0.54 – $2.18). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 8% of its 52-week range ($0.54 – $2.18) with RSI-14 at 47.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.67 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RNTX Headlines & Catalysts
MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 1h ago
US voters in a sour economic mood heading into midterm elections - ReutersUS voters in a sour economic mood heading into midterm elections Reuters
MARKET WIREReuters • 2h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
MARKET WIREReuters • 5h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 6h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 7h ago
Gold rebounds from one-year low as oil slides ahead of US midterms - ReutersGold rebounds from one-year low as oil slides ahead of US midterms Reuters
MARKET WIREReuters • 8h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNTX)
- ✓Walkthrough of RNTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RNTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.74%▼ DESCENDING CHANNEL
2026-10-30O $0.70H $0.70L $0.66C $0.67VOL 121.5K
RES: $0.83SUP: $0.46SMA50: $0.75SMA200: $1.04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RNTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RNTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RNTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RNTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNTX)
Health Care Rank #315 of 1016
⚔️ INCR vs RNTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RNTX vs. INCR, SPRO, CPIX, APLM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Rein Therapeutics Inc. (RNTX) ranks #315 by composite RQD confidence (49/100, grade D) and #722 by equity capitalization ($62.7M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with RNTX at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RNTX
ACTIVE
Rein Therapeutics Inc. | D | 49/100 | — | — | -35.0% | -7.79% | $62.7M | Benchmark Subject |
| INCR Intercure Ltd. | D | 48/100 | — | — | — | -3.64% | $61.8M | /incr-vs-rntx → |
| SPRO Spero Therapeutics Inc. | D- | 43/100 | 7.5x | — | 26.6% | -4.50% | $64.6M | /spro-vs-rntx → |
| CPIX Cumberland Pharmaceuticals Inc. | D- | 38/100 | — | 85.0% | -16.4% | +7.82% | $65.2M | /cpix-vs-rntx → |
| APLM Apollomics Inc. (Class A) | C | 62/100 | — | — | — | -0.53% | $60.2M | /aplm-vs-rntx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001420565In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rein Therapeutics Inc. (RNTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$49.9M, operating cash flow of -$19.4M, and free cash flow of -$19.4M (+13.1% YoY). On the balance sheet, RNTX closed FY2025 with $24.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$49.9M | -$19.4M | -$19.4M | $24.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$62.9M | -$22.3M | -$22.3M | $62.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$15.7M | -$19.8M | -$19.8M | — | — |
3. RNTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RNTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Rein Therapeutics Inc. (NASDAQ: RNTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.67 (-7.79% 1D, market cap $62.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RNTX ranks #315 in composite RQD confidence.
How does RNTX compare to INCR and SPRO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNTX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INCR (Intercure Ltd.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $61.8M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RNTX?
Per RNTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001420565), Rein Therapeutics Inc. generated $0 in revenue, -$49.9M in net income, and -$19.4M in free cash flow against $24.2M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RNTX trading relative to its 50-day, 200-day, and 52-week technical levels?
RNTX last traded at $0.67 (-7.79% on volume of 121,464 shares), positioning the stock -10.67% below its 50-day simple moving average ($0.75) and -35.58% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.54 to $2.18, RNTX sits at the 7.9% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.75).
RNTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RNTX stock moving today?
Why RNTX Stock dropped -7.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.